IP Verse

Salt Of Omecamtiv Mecarbil And Process For Preparing Salt - EP2970123

The patent EP2970123 was granted to Amgen on Aug 14, 2019. The application was originally filed on Mar 14, 2014 under application number EP14720369A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2970123

AMGEN
Application Number
EP14720369A
Filing Date
Mar 14, 2014
Status
Granted And Under Opposition
Jul 12, 2019
Grant Date
Aug 14, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KELTIEMay 14, 2020MOOREADMISSIBLE

Patent Citations (4) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2006014761
INTERNATIONAL-SEARCH-REPORTWO2007070683
INTERNATIONAL-SEARCH-REPORTWO2009138438
OPPOSITIONUS2006014761

Non-Patent Literature (NPL) Citations (6) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Cleland, J.G.F. et al., The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure, a double-blind, placebo-controlled, crossover, dose-ranging phase2 trial. The Lancet (2011), vol 378, p. 676-683-
OPPOSITION- Extract from "Polymorphism in Pharmaceutical Solids", Brittain, H.G. (editor), Marcel Dekker, Inc.(2008), p. 17-18-
OPPOSITION- Hellriegel. E.T. et al., Clinical Pharmacology & Therapeutics, vol 60, no 6 (1996), p 601-607-
OPPOSITION- James, J S., Ritonavir capsule manufacturing problems will require switch to liquid formulation AIDSTreat News (1998), No 300, 1, 5-
OPPOSITION- Stability testing of active pharmaceutical ingredients and finished pharmaceutical products Annex 2 in the World Health Organization (WHO) Technical Report Series, No 953, (2009) p87 100-102-
OPPOSITION- Teerlink, J.R. et al., The Lancet, vol. 378 (2011), p. 667-675-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents